Insulin sensitisers are oral anti-diabetic drugs that improve the body's response to insulin. They help control blood sugar levels in patients with type 2 diabetes. Insulin sensitisers play a crucial role in the management of diabetes by reducing insulin resistance and helping cells to better utilize insulin. Some commonly used insulin sensitisers include metformin, pioglitazone, and rosiglitazone. They are usually prescribed as first-line therapy for type 2 diabetes due to their effectiveness and minimal risk of hypoglycemia when compared to insulin and sulfonylureas.
The global Insulin Sensitizers Market is estimated to be valued at US$ 15.09 Bn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing prevalence of diabetes across the world is the major factor driving the growth of the insulin sensitisers market. According to the International Diabetes Foundation, around 537 million adults were living with diabetes globally in 2021 and this number is projected to rise to 643 million by 2030 and 784 million by 2045, with type 2 diabetes making up approximately 90% of the cases. Increased adoption of sedentary lifestyle and unhealthy eating habits have significantly contributed to the rising incidence of obesity and diabetes. Since insulin sensitisers are first-line medications for type 2 diabetes, growing diabetes population base is expected to propel the demand for insulin sensitisers during the forecast period. Moreover, favorable reimbursement policies and availability of generic versions of insulin sensitisers will also support the market growth over the coming years.
Segment Analysis
The global insulin sensitizers market is dominated by the thiazolidinediones segment. Within the thiazolidinediones segment, pioglitazone holds the largest share due to its effectiveness in improving insulin sensitivity. Pioglitazone treats type 2 diabetes and helps control blood sugar levels in patients. It works by improving the body's response to insulin production and decreasing glucose production in the liver.
Key Takeaways
Global Insulin Sensitizers Market Size is expected to witness high growth over the forecast period owing to the rising prevalence of diabetes worldwide.
Regional analysis: North America currently dominates the global market and is expected to grow at a high rate during the forecast period. This is attributed to the increasing incidence of diabetes and growing obese population in the US and Canada. Europe holds the second position in the global market due to growing awareness about diabetes treatment and management. The Asia Pacific region is projected to grow at the fastest pace during the forecast period driven by the rising geriatric population, growing health awareness, and increasing expenditures on diabetes care.
Key players: Key players operating in the insulin sensitizers market are Nike, Adidas, Puma, Under Armour, New Balance, ASICS, VF Corporation, Lululemon, Columbia Sportswear, Ralph Lauren, Li Ning, L Brands, H&M, Zara, Uniqlo, Forever21, Gap, Next, Esprit, and C&A. Nike has a strong brand presence worldwide and leads the athletic footwear and apparel market. Adidas holds a significant market share in the running and outdoor sports categories. Puma is a leading brand in lifestyle and athletic footwear & clothing.
Get More Insights On This Topic: https://www.ukwebwire.com/insulin-sensitizers-market-share/
